• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • View Item
  •   LillOA Home
  • Liste des unités
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Anti-diabetic activity of fused PPAR ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique
DOI :
10.1016/j.ejmech.2017.136.006
PMID :
28609708
Permalink :
http://hdl.handle.net/20.500.12210/11285
Title :
Anti-diabetic activity of fused PPAR gamma-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression
Author(s) :
Pirat, Celine [Auteur]
Dacquet, Catherine [Auteur]
Leclerc, Veronique [Auteur]
Hennuyer, Nathalie [Auteur]
Beucher-Gaudin, Monique [Auteur]
Zanirato, Ghislaine [Auteur]
Geant, Anne [Auteur]
Staels, Bart [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011
Ktorza, Alain [Auteur]
Farce, Amaury [Auteur] refId
Lille Inflammation Research International Center - U 995 [LIRIC]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Caignard, Daniel-Henri [Auteur]
Berthelot, Pascal [Auteur]

Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Lebegue, Nicolas [Auteur]

Lille Neurosciences & Cognition (LilNCog) - U 1172
Journal title :
European journal of medicinal chemistry
Abbreviated title :
Eur. J. Med. Chem.
Volume number :
137
Pages :
310-326
Publication date :
2017-09-08
ISSN :
0223-5234
English keyword(s) :
SGK1
SIRT1
PPAR
Diabetes
Resveratrol
Calorie restriction
Body-weight gain
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
A series of benzothiazol-2-one containing α-ethoxyphenylpropionic acid derivatives incorporating resveratrol or butein scaffolds were designed as fused full PPARγ agonist ligands and SIRT1-activating compounds for the ...
Show more >
A series of benzothiazol-2-one containing α-ethoxyphenylpropionic acid derivatives incorporating resveratrol or butein scaffolds were designed as fused full PPARγ agonist ligands and SIRT1-activating compounds for the treatment of type 2 diabetes (T2D) and its complications. Compound 14d displayed the best in vitro pharmacological profile with full PPARγ agonist activity (Emax = 98%, EC = 200 nM), SIRT1 enzymatic activation (+128%) and SGK1 expression inhibition (- 57%) which is known to limit side effects as fluid retention and body-weight gain. Compound 14d showed high efficacy in an ob/ob mice model with significant decreases in serum triglyceride, glucose and insulin levels but mostly with limited body-weight gain by mimicking calorie restriction (CR) and inhibiting SGK1 expression.Show less >
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Institut Pasteur de Lille
Collections :
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • Lille Neurosciences & Cognition (LilNCog) - U 1172
  • Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (EGID) - U1011
Research team(s) :
Therapeutic innovation targetting inflammation
Submission date :
2019-05-17T13:14:42Z
Université de Lille

Mentions légales
Université de Lille © 2017